EksoNR is a robotic exoskeleton designed specifically for use in rehabilitation facilities for MS patients. It is the first exoskeleton in rehabilitation with FDA approval for MS patients.
Everything you need to know about the features and benefits of the Exoskeleton EksoNR for rehabilitation facilities need to know.
Ekso Bionics (Nasdaq:EKSO) announced that it has received FDA 510(k) clearance for its EksoNR robotic exoskeleton.
Richmond, California-based Ekso Bionics has developed EksoNR technology for use in patients with multiple sclerosis (MS).
According to a press release, EksoNR is the first exoskeleton approved by the FDA for the rehabilitation of MS patients, greatly expanding the device's use to a broader patient population.
The latest generation of the Ekso Bionics platform, the EksoNR, received approval for stroke and spinal cord rehabilitation in 2016 and acquired brain injury (ABI) in 2020. According to Ekso, it was the first of its kind to receive a stroke indication, and it is the only exoskeleton with indications for ABI and now MS. EksoNR also has the CE mark, the company said.
"As a leader in wearable robotic solutions for medical rehabilitation, we are committed to maximizing patient access to our technology," Steven Sherman, chairman and CEO of Ekso Bionics, said in the press release. "With the expansion of applications to MS, the EksoNR has the potential to help many more patients and improve their mobility. We look forward to the device benefiting MS patients and providing them with much-needed rehabilitation solutions, as it has done for patients with stroke, spinal cord injury and acquired brain injury."
The EksoNR exoskeleton is designed to support correct posture and a natural gait, allowing therapists to focus on the individual needs of their patients. Its high, stable back and choice of advanced modes make it an excellent choice for individuals with acquired brain injury (ABI) and stroke patients just beginning to walk, as well as patients with multiple sclerosis (MS) working to maintain quality gait mechanics. The EksoNR exoskeleton combines advanced technology with a personalized approach to patient needs, providing a highly effective solution for people looking to improve mobility and regain independence.
During your training session, you can keep track of your walking time, distance covered and speed - everything is stored in a secure cloud-based system and is easy to evaluate. This training device shows you your walking time, distance covered and speed during your session - the data is stored reliably in a cloud-based system and is easy to evaluate.
The EksoNR posture correction allows the patient to carry his own weight and the treatment time becomes more effective. EksoNR ensures that the patient only has to carry his own weight and the treatment time is utilized as much as possible.
Adjust motor support according to the respective degree of impairment: from full support to patient-initiated movements, both in the swing and stance phases of walking. Adjust motor support according to the respective degree of impairment: from full support to patient-initiated movements, both in the swing and stance phases of walking.
Sensors and software continuously monitor and regulate leg movement to create a gentle posture.
Ekso gait training improves the functional balance of people with incomplete paraplegia.
Research shows that rehabilitation patients who have completed Ekso gait training as part of their rehab can walk longer distances without the device at discharge than patients who do not complete Ekso gait training. Rehabilitation patients who complete Ekso gait training can travel longer distances after rehab than patients who do not complete Ekso gait training.
Over 300 devices in over 30 countries worldwide.
Ekso is suitable for patients weighing up to 100 kg and between 1.50 m and 2 m tall.
Ekso comes with two sets of rechargeable lithium-ion batteries that allow uninterrupted use.
Ekso Bionics exoskeletons are only suitable for persons with a body height between 1.50 m and 2 m.
No, Ekso is only approved for use in certified rehabilitation facilities.
Can't find the answer to your question? Contact us.
The company was founded in 2015 and is based in Hamburg, Germany. Ekso Bionics acquires the exoskeleton, human motion and control businesses of Parker Hannifin (Indego). Ekso Bionics has raised a total of $187.9 million in 13 rounds of financing. The most recent financing was on February 11, 2021, in a post-IPO equity round.Ekso Bionics is registered under the ticker NASDAQ:EKSO. Ekso Bionics is funded by 5 investors. Bridge Bank and Montrose Capital Partners are the latest investors.
Image sources: All images and graphics are copyrighted and property of ©.